@article { author = {}, title = {A Pooled Analysis on Crizotinib in Treating Chinese Patients with EML4-ALK Positive Non-small-cell Lung Cancer}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {16}, number = {11}, pages = {4797-4800}, year = {2015}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {}, abstract = {Background: This analysis was conducted to evaluate the efficacy and safety of crizotinib based regimens intreating Chinese patients with EML4-ALK positive non-small-cell lung cancer. Materials and Methods: Clinicalstudies evaluating the efficacy and safety of crizotinib based regimens on response and safety for Chinese patientswith EML4-ALK positive non-small-cell lung cancer were identified by using a predefined search strategy.Pooled response rate (RR) of treatment were calculated. Results: In crizotinib based regimens, 3 clinical studieswhich including 128 Chinese patients with EML4-ALK positive non-small-cell lung cancer and treated withcrizotinib based regimen were considered eligible for inclusion. Pooled analysis suggested that, in all patients,the pooled RR was 59.3% (76/128) in crizotinib based regimens. ALT/AST mild visual disturbances, nausea, andvomiting were the main side effects. No treatment related death occurred in these crizotinib based treatments.Conclusions: This pooled analysis suggests that crizotinib based regimens are associated with good responserate and accepted toxicities in treating Chinese patients with EML4-ALK positive non-small-cell lung cancer.}, keywords = {crizotinib,second-line chemotherapy,EML4-ALK positive non-small-cell lung cancer}, url = {https://journal.waocp.org/article_31164.html}, eprint = {https://journal.waocp.org/article_31164_881d7b9d542ce42351dc25ba55be9c92.pdf} }